{"id":"chemotherapy-imatinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Fluid retention"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:53:28.154757","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Chemotherapy agents work through various mechanisms (DNA damage, microtubule disruption) to induce apoptosis in cancer cells. Imatinib is a tyrosine kinase inhibitor that specifically targets BCR-ABL fusion protein (characteristic of chronic myeloid leukemia and some acute leukemias) and other kinases, blocking downstream signaling pathways essential for leukemic cell survival and proliferation. The combination approach leverages complementary mechanisms to improve efficacy in hematologic malignancies.","oneSentence":"This combination uses chemotherapy to kill rapidly dividing cancer cells while imatinib inhibits BCR-ABL and other tyrosine kinases to block leukemic cell proliferation and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:34.091Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL) in combination with chemotherapy"},{"name":"Chronic myeloid leukemia (CML)"},{"name":"Acute myeloid leukemia (AML) with BCR-ABL or other kinase-driven disease"}]},"_fixedFields":["pubmed(2)","modality→Small Molecule"],"trialDetails":[{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT05306301","phase":"PHASE2","title":"Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2022-10-05","conditions":"Chemotherapy, Leukemia, Acute Lymphoblastic","enrollment":32},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT03589326","phase":"PHASE3","title":"A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2018-10-04","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)","enrollment":245},{"nctId":"NCT01771458","phase":"PHASE2","title":"A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2012-10","conditions":"Reccurent/Metastatic Solid Tumor Disease","enrollment":742},{"nctId":"NCT05071482","phase":"PHASE4","title":"Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL","status":"TERMINATED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-09-16","conditions":"Acute Leukemia","enrollment":39},{"nctId":"NCT06061094","phase":"PHASE2","title":"Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT","status":"RECRUITING","sponsor":"Goethe University","startDate":"2023-07-14","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT03632135","phase":"PHASE3","title":"Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Cordgenics, LLC","startDate":"2018-05-20","conditions":"Recurrent Glioblastoma","enrollment":78},{"nctId":"NCT01085617","phase":"","title":"Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University College, London","startDate":"2010-12","conditions":"Leukemia, Mucositis, Oral Complications","enrollment":""},{"nctId":"NCT06038552","phase":"","title":"Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2002-01-01","conditions":"GIST, Malignant, Liver Metastases","enrollment":238},{"nctId":"NCT04722848","phase":"PHASE3","title":"Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2021-09-08","conditions":"Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL","enrollment":236},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT06051409","phase":"PHASE3","title":"A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2023-08-31","conditions":"Ph+ ALL","enrollment":350},{"nctId":"NCT06175702","phase":"","title":"Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2023-12-25","conditions":"Lymphoblastic Leukemia, Philadelphia-Positive ALL, Adult ALL","enrollment":150},{"nctId":"NCT01616238","phase":"PHASE2","title":"A Study for Older Adults With Acute Lymphoblastic Leukaemia","status":"COMPLETED","sponsor":"University College, London","startDate":"2012-12","conditions":"Acute Lymphoblastic Leukaemia","enrollment":126},{"nctId":"NCT00002514","phase":"PHASE3","title":"Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1993-05-07","conditions":"Leukemia","enrollment":1929},{"nctId":"NCT00287105","phase":"PHASE2","title":"Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2005-12","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome","enrollment":49},{"nctId":"NCT00744081","phase":"PHASE2","title":"Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Goethe University","startDate":"2004-07","conditions":"AML","enrollment":130},{"nctId":"NCT05743465","phase":"","title":"A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-10-06","conditions":"Leukemia","enrollment":1769},{"nctId":"NCT00573378","phase":"PHASE2","title":"Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2007-09","conditions":"Chronic Myeloid Leukemia","enrollment":12},{"nctId":"NCT01005914","phase":"PHASE2","title":"Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2009-06","conditions":"Leukemia","enrollment":11},{"nctId":"NCT01319981","phase":"PHASE2","title":"Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-03-05","conditions":"Leukemia","enrollment":31},{"nctId":"NCT03023046","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"University of Washington","startDate":"2017-02-23","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":54},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT00061945","phase":"PHASE1, PHASE2","title":"Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-06","conditions":"Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia","enrollment":302},{"nctId":"NCT02462538","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL","status":"TERMINATED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2015-11-03","conditions":"ALK+ Anaplastic Large Cell Lymphoma","enrollment":3},{"nctId":"NCT01491763","phase":"PHASE4","title":"Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2008-01","conditions":"Acute Lymphoblastic Leukemia Ph Positive","enrollment":70},{"nctId":"NCT01271712","phase":"PHASE3","title":"Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01-04","conditions":"Gastrointestinal Stromal Tumors","enrollment":199},{"nctId":"NCT04688983","phase":"PHASE2","title":"Study in Adult Ph-positive ALL","status":"UNKNOWN","sponsor":"Cardiff University","startDate":"2021-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":180},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT00137111","phase":"PHASE3","title":"Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2000-07-08","conditions":"Lymphoblastic Leukemia, Acute","enrollment":501},{"nctId":"NCT02638428","phase":"PHASE2","title":"Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2015-12","conditions":"Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Relapsed Pediatric AML","enrollment":90},{"nctId":"NCT00509093","phase":"PHASE2","title":"Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2008-10","conditions":"Leukemia","enrollment":32},{"nctId":"NCT02611492","phase":"PHASE3","title":"A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04","conditions":"Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia","enrollment":265},{"nctId":"NCT00167180","phase":"PHASE2","title":"Post Transplant Donor Lymphocyte Infusion","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2004-01","conditions":"Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma","enrollment":57},{"nctId":"NCT03062436","phase":"NA","title":"To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission","status":"UNKNOWN","sponsor":"Command Hospital, India","startDate":"2017-08-01","conditions":"Chronic Myeloid Leukemia, Treatment Free Remission","enrollment":27},{"nctId":"NCT00458848","phase":"PHASE2","title":"Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2004-10","conditions":"Leukemia","enrollment":470},{"nctId":"NCT01312818","phase":"PHASE2","title":"Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":2},{"nctId":"NCT00882206","phase":"PHASE2","title":"Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2009-04","conditions":"Leukemia, Lymphoma","enrollment":15},{"nctId":"NCT03331211","phase":"","title":"Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2017-11-01","conditions":"Leukemia, Lymphoblastic, Acute","enrollment":100},{"nctId":"NCT02342600","phase":"PHASE2","title":"SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)","status":"WITHDRAWN","sponsor":"Sarcoma Alliance for Research through Collaboration","startDate":"2017-01","conditions":"Gastrointestinal Stromal Tumors","enrollment":""},{"nctId":"NCT00408460","phase":"PHASE2","title":"Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-02","conditions":"Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer","enrollment":34},{"nctId":"NCT00815321","phase":"PHASE2","title":"Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2008-12","conditions":"Chronic Myeloid Leukemia","enrollment":11},{"nctId":"NCT00372476","phase":"PHASE4","title":"Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-06","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT00327678","phase":"PHASE3","title":"Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2006-05","conditions":"Leukemia, Lymphocytic","enrollment":1080},{"nctId":"NCT01323400","phase":"PHASE2","title":"Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2011-03","conditions":"GIST","enrollment":81},{"nctId":"NCT00538109","phase":"NA","title":"An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2007-10","conditions":"Leukemia, Myeloid, Chronic","enrollment":8},{"nctId":"NCT00038610","phase":"PHASE2","title":"Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-03","conditions":"Leukemia","enrollment":54},{"nctId":"NCT00052494","phase":"PHASE1","title":"Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2003-04","conditions":"Lung Cancer","enrollment":9},{"nctId":"NCT01126814","phase":"PHASE1, PHASE2","title":"A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2004-07","conditions":"Leukemia","enrollment":35},{"nctId":"NCT00039377","phase":"PHASE2","title":"Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-04","conditions":"Adult Acute Lymphoblastic Leukemia in Remission","enrollment":58},{"nctId":"NCT00928642","phase":"PHASE2","title":"Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2009-06","conditions":"Ovarian Cancer, Primary Peritoneal Cancer","enrollment":8},{"nctId":"NCT02127372","phase":"PHASE1, PHASE2","title":"Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571","status":"TERMINATED","sponsor":"Duke University","startDate":"2004-11","conditions":"Non-small Cell Lung Cancer","enrollment":43},{"nctId":"NCT00424385","phase":"PHASE1","title":"Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)","status":"COMPLETED","sponsor":"Oncology Specialists, S.C.","startDate":"2007-01","conditions":"Prostate Cancer","enrollment":17},{"nctId":"NCT00955916","phase":"PHASE2","title":"CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2009-08","conditions":"Leukemia","enrollment":38},{"nctId":"NCT00022737","phase":"PHASE3","title":"Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-10","conditions":"Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT01005758","phase":"PHASE2","title":"Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2009-01","conditions":"Leukemia","enrollment":180},{"nctId":"NCT00359333","phase":"PHASE2","title":"Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2006-12","conditions":"Sarcoma, Malignant Gastrointestinal Stromal Tumor","enrollment":58},{"nctId":"NCT00049569","phase":"NA","title":"Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-01","conditions":"L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Non-T, Non-B Childhood Acute Lymphoblastic Leukemia","enrollment":126},{"nctId":"NCT00015860","phase":"PHASE1, PHASE2","title":"STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2001-05","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00425646","phase":"PHASE2","title":"Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-11","conditions":"Lung Cancer","enrollment":50},{"nctId":"NCT00618501","phase":"PHASE2","title":"Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2005-10","conditions":"Leukemia","enrollment":50},{"nctId":"NCT01222013","phase":"PHASE2","title":"Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)","status":"SUSPENDED","sponsor":"Renato Melaragno","startDate":"","conditions":"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)","enrollment":20},{"nctId":"NCT01148134","phase":"","title":"Pharmacokinetic Profile of Vincristine Administered With Imatinib for Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib for Bcr-Abl Negative ALL","status":"TERMINATED","sponsor":"University Health Network, Toronto","startDate":"2010-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":10},{"nctId":"NCT00688766","phase":"PHASE3","title":"Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib","status":"TERMINATED","sponsor":"Infinity Pharmaceuticals, Inc.","startDate":"2008-08","conditions":"Gastrointestinal Stromal Tumors","enrollment":47},{"nctId":"NCT01048320","phase":"PHASE1","title":"Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer","status":"COMPLETED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2006-07","conditions":"Advanced Pancreatic Cancer","enrollment":36},{"nctId":"NCT00244829","phase":"PHASE1, PHASE2","title":"Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2004-01","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00763763","phase":"PHASE2","title":"Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2004-12","conditions":"Leukemia, Lymphocytic, Acute, Philadelphia Chromosome, Blast Crisis","enrollment":55},{"nctId":"NCT01153750","phase":"PHASE2","title":"Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct","status":"COMPLETED","sponsor":"University Hospital Dresden","startDate":"2007-04","conditions":"Advanced or Metastatic Cholangiocellular Carcinoma and Bile Duct","enrollment":44},{"nctId":"NCT00388895","phase":"PHASE2","title":"Glivec in Ph Positive Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2002-06","conditions":"Acute Lymphoblastic Leukemia, Cromosome Philadelphia Positive","enrollment":35},{"nctId":"NCT00130195","phase":"PHASE2","title":"Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Japan Adult Leukemia Study Group","startDate":"2002-09","conditions":"Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT00045604","phase":"PHASE1","title":"Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2002-07","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT00199186","phase":"PHASE2","title":"Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)","status":"UNKNOWN","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2002-03","conditions":"Philadelphia Positive Acute Lymphoblastic Leukemia, Lymphoid Blastic Phase of Chronic Myeloid Leukemia","enrollment":""},{"nctId":"NCT00149136","phase":"PHASE2","title":"Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2002-08","conditions":"Acute Lymphocytic Leukemia","enrollment":30},{"nctId":"NCT00219765","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients","status":"TERMINATED","sponsor":"Poitiers University Hospital","startDate":"2001-05","conditions":"Chronic Myeloid Leukemia","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"recentPublications":[{"date":"2026 Jan 12","pmid":"41405203","title":"Phase III Data Support Chemo-Free Approach to ALL.","journal":"Cancer discovery"},{"date":"2013 Jul","pmid":"23863741","title":"[A case of a giant rectal gastrointestinal stromal tumor radically resectable after treatment with neoadjuvant imatinib mesylate].","journal":"Gan to kagaku ryoho. Cancer & chemotherapy"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Chemotherapy + Imatinib","genericName":"Chemotherapy + Imatinib","companyName":"Gruppo Italiano Malattie EMatologiche dell'Adulto","companyId":"gruppo-italiano-malattie-ematologiche-dell-adulto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses chemotherapy to kill rapidly dividing cancer cells while imatinib inhibits BCR-ABL and other tyrosine kinases to block leukemic cell proliferation and survival. Used for Acute lymphoblastic leukemia (ALL) in combination with chemotherapy, Chronic myeloid leukemia (CML), Acute myeloid leukemia (AML) with BCR-ABL or other kinase-driven disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}